SCHEMBL6492248

SCHEMBL6492248

c1ccc2c(CNc3ccc4[nH]c5ccccc5c4c3)cccc2c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MC5R P33032 1/20 0.47
MC1R Q01726 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
AHR P35869 1/20 0.43
CA2 P00918 1/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 2/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
KIF11 P52732 2/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493014 0.83 KMT2A (0.50) KMT2AKDM4EMTNR1AMTNR1BMAPT
SCHEMBL6497640 0.83 KMT2A (0.49) KMT2AKDM4EMTNR1AMTNR1BMAPT
SCHEMBL6483228 0.81 MAPT (0.51) KMT2AKDM4EMTNR1AMTNR1BMAPT
SCHEMBL6484782 0.79 GABRA1 (0.61) KMT2AMC5RMC1RKDM4EMTNR1A
SCHEMBL28416582 0.79 HDAC1 (0.56) KMT2AMAPTALDH1A1LMNAMEN1
SCHEMBL6485068 0.78 MAPT (0.56) KMT2AKDM4EMAPTALDH1A1LMNA
SCHEMBL6775812 0.77 MAPT (0.43) KMT2AMC5RMAPTALDH1A1LMNA
SCHEMBL6492565 0.77 KMT2A (0.47) KMT2AKDM4EMTNR1AMTNR1BMAPT
SCHEMBL3742086 0.77 LMNA (0.49) KMT2AMC5RMC1RMAPTALDH1A1
SCHEMBL6496788 0.77 GAA (0.46) KMT2AKDM4EMTNR1AMTNR1BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 KMT2A 412/4885MC5R 2608/4885MC1R 1981/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 KMT2A 770/4885MC5R 2753/4885MC1R 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.